Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F5Q31
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,023
Award facts
- Contract value 100% obligated
- $27,022.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $27,022.65 under a firm fixed price contract type. The award was made on November 28, 2025, with an ultimate completion date of December 1, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies comprehensive pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company holds a significant $999,999,999.00 IDC with DLA Troop Support Medical (designated SPE2DX) running through December 2026, which serves as a global pharmaceutical support vehicle enabling the supply of specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for Dupixent, a biologic immunosuppressant therapy commonly used to treat conditions such as atopic dermatitis and eosinophilic asthma, exemplifies AmerisourceBergen's role in ensuring medical product availability across the Defense Health Agency and broader federal healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F5Q31?
SPE2DR26F5Q31 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26F5Q31 worth?
The government has obligated $27,023 on SPE2DR26F5Q31.
Is contract SPE2DR26F5Q31 an order under another contract?
Yes. SPE2DR26F5Q31 is a delivery order under SPE2DR25D3101, an indefinite delivery contract.
Was contract SPE2DR26F5Q31 competed?
The extent of competition for SPE2DR26F5Q31 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award